Brattea key facts
as of Oct 2026- Developer of hypertension interventional devices designed for medical health.
- Brattea is valued at approximately $422.3M as of Oct 2026 (last reported valuation).
- It has raised $144.3M; the latest was Later Stage VC ($20.6M) in Feb 2025.
- Notable investors include SAIC Capital China, Northern Light Venture Capital, Dalton Venture, CCB International, Shanghai Healthcare Capital — 20 tracked in total.
- Status: Privately Held (backing).
Brattea's last reported valuation, Feb 2025. Nothing priced has surfaced since.
- ·The complete investor list: 20 names
- ·Watch Brattea: the Monday email on marks, rounds and moves
Brattea funding rounds
No funding rounds for Brattea are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Brattea
20+Brattea valuation
Brattea's last reported valuation was $422 million in Feb 2025. No priced round, secondary trade or fund mark has surfaced since.
Brattea investors
20 investors are on record for Brattea, including SAIC Capital China, Northern Light Venture Capital, Dalton Venture and CCB International. By type, the record holds 3 venture capital firms and 2 private equity firms.
About Brattea
Developer of hypertension interventional devices designed for medical health. The company has products including renal artery ablation catheter, radiofrequency ablation equipment, and other medical mapping system equipment, which can offer treatment of refractory hypertension, obstructive sleep apnea, kidney disease, heart failure, etc, providing custimers with reliable products.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2013
- Employees
- 19
- Website
- brattea.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.